Merck KGaA, Darmstadt, Germany: Carcinoma, Non-Small-Cell Lung trials

The registry lists 29 Carcinoma, Non-Small-Cell Lung studies with Merck KGaA, Darmstadt, Germany as lead sponsor. 1 are open to participants now and 20 have results posted.

Phase 1 12Phase 2 13Phase 3 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid TumorsRecruitingNCT07166601Phase 1
• A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)CompletedNCT03940703Phase 2Results posted
• M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)CompletedNCT03840915Phase 1/2Results posted
• M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)TerminatedNCT03840902Phase 2Results posted
• Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLCCompletedNCT03717155Phase 2Results posted
• M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT03631706Phase 3Results posted
• Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)Active, not recruitingNCT02864992Phase 2Results posted
• Avelumab in First-line NSCLC (JAVELIN Lung 100)CompletedNCT02576574Phase 3Results posted
• Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)CompletedNCT02395172Phase 3Results posted
• Sym004 in Subjects With Stage IV Non-small Cell Lung CancerTerminatedNCT02083679Phase 1Results posted
• Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung CancerTerminatedNCT02049151Phase 3Results posted
• Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)CompletedNCT01982955Phase 1/2Results posted
• Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian PopulationTerminatedNCT01015443Phase 3Results posted
• Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary ChemoradiotherapyCompletedNCT00960115Phase 1/2Results posted
• Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)CompletedNCT00842712Phase 2Results posted
• Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)CompletedNCT00820755Phase 3Results posted
• Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)CompletedNCT00409188Phase 3Results posted
• Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)CompletedNCT00157209Phase 2Results posted
• Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III DiseaseCompletedNCT00157196Phase 2Results posted
• Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)CompletedNCT00148798Phase 3Results posted
• Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung CancerCompletedNCT00111839Phase 2Results posted
• Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)Active, not recruitingNCT06710132Phase 1/2
• Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)CompletedNCT05882734Phase 1/2
• M1231 in Participants With Solid TumorsCompletedNCT04695847Phase 1
• Avelumab Program Rollover StudyActive, not recruitingNCT03815643Phase 3
• Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung CancerWithdrawnNCT01731587Phase 1
• EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC)CompletedNCT00879866Phase 1
• Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLCCompletedNCT00633529Phase 1
• EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given CyclophosphamideCompletedNCT00132522Phase 1